Daily Respiratory Research Analysis
Analyzed 64 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies stood out: a phase III RCT (JCOG1205/1206) shows no difference between irinotecan–cisplatin and etoposide–cisplatin as adjuvant therapy for resected high-grade lung neuroendocrine carcinoma; a multicenter case-control study demonstrates a high-performing urinary EV–miRNA assay for early lung cancer detection and recurrence monitoring; and a randomized clean-cooking intervention in Guatemala finds no effect on prespecified oscillometry outcomes at age 3, with exploratory signals of lower airway resistance.
Research Themes
- Adjuvant chemotherapy optimization in resected high-grade neuroendocrine lung cancer
- Noninvasive biomarker development for early lung cancer detection and surveillance
- Early-life environmental interventions and pediatric lung function
Selected Articles
1. Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
In this phase III RCT of 221 patients with completely resected high-grade pulmonary neuroendocrine carcinoma, adjuvant irinotecan–cisplatin and etoposide–cisplatin yielded similar 5-year RFS and OS. Findings provide definitive negative evidence that neither regimen is superior for long-term outcomes.
Impact: A definitive randomized trial in a rare lung cancer subtype informs adjuvant regimen selection and sets a benchmark for future trials.
Clinical Implications: Both EP and IP are acceptable adjuvant options; regimen choice may be guided by toxicity profiles, logistics, and patient preference. These results underscore the need to test novel systemic strategies in resected HGNEC.
Key Findings
- No significant difference in 5-year RFS between EP (65.7%) and IP (65.2%); HR 1.026 (95% CI 0.670–1.569).
- No significant difference in 5-year OS between EP (73.5%) and IP (72.4%); HR 1.175 (95% CI 0.742–1.861).
- Central vs institutional pathology diagnosis concordance was 75.6%, highlighting diagnostic variability.
Methodological Strengths
- Randomized, phase III, parallel-group comparison with long-term follow-up.
- Central pathology review to assess diagnostic concordance.
Limitations
- Open-label design may introduce bias, though survival endpoints are objective.
- Rare-disease context limits power to detect small differences; pathology concordance at 75.6% implies heterogeneity.
Future Directions: Evaluate novel adjuvant strategies (e.g., immunotherapy or molecularly selected regimens) and improve pathological and molecular classification to reduce heterogeneity.
INTRODUCTION: We aimed to evaluate the long-term follow-up overall survival (OS) of irinotecan plus cisplatin (IP) versus etoposide plus cisplatin (EP) as postoperative adjuvant chemotherapy in patients with pathological Stage I-IIIA high-grade neuroendocrine carcinoma (HGNEC) of the lung. METHODS: The JCOG1205/1206 randomized, open-label, phase III study compared the efficacy of IP and EP as adjuvant chemotherapy. Patients with pathological Stage I-IIIA and completely resected HGNEC of the lung were randomized to receive either the IP or EP arm. The primary endpoint was relapse-free survival (RFS), and the secondary endpoint included overall survival (OS). The analyses were performed using data from 5 years after the last patient enrollment. In addition, a central pathological review was planned for this study. RESULTS: Between April 2013 and October 2018, 221 patients were enrolled (EP arm, 111 patients; IP arm, 110 patients). Updated respective 3- and 5-year RFS rates were 68.5% and 65.7% in the EP arm versus 71.8% and 65.2% in the IP arm, with a hazard ratio (HR) of 1.026 (95% confidence interval [CI], 0.670-1.569). OS at 3 and 5 years was 85.6% and 73.5%, respectively, in the EP arm versus 83.6% and 72.4%, respectively, in the IP arm (HR, 1.175; 95% CI, 0.742-1.861). The concordance proportion of pathological diagnoses between each institution and central pathological reviews was 75.6% (95% CI, 69.4%-81.1%). CONCLUSIONS: Our results showed no significant difference in both updated RFS and OS between the two arms for patients with completely resected HGNEC.
2. A noninvasive urinary microRNA-based assay for early detection of lung cancer and its potential application to prognosis and recurrence monitoring: a case-control study.
A multicenter urinary EV–miRNA panel accurately detected lung cancer, including early-stage disease, with AUC ~0.94 and robust sensitivity/specificity in an internal test set. Serial changes after surgery and at recurrence, plus a 3-miRNA prognostic panel, suggest utility for surveillance and risk stratification.
Impact: Introduces a noninvasive, scalable biomarker platform with strong diagnostic and prognostic signals for lung cancer.
Clinical Implications: If validated prospectively, urinary EV–miRNA testing could support early detection triage, complement low-dose CT, and enable minimally invasive recurrence monitoring.
Key Findings
- Diagnostic model achieved AUC 0.942 (training) and 0.941 (test) for lung cancer detection.
- For early-stage lung cancer, sensitivity/specificity were 82.0%/92.5% (training) and 88.2%/87.0% (test).
- Twelve miRNAs decreased after surgery and rose at recurrence; eleven miRNAs associated with recurrence-free survival; a 3-miRNA panel stratified risk.
- Observed cohort differences (age, sample storage) acknowledged as potential sources of bias.
Methodological Strengths
- Multicenter design with independent training/test cohorts and machine-learning model development.
- Biological validation via perioperative dynamics and association with recurrence-free survival.
Limitations
- Case-control design risks spectrum and selection bias; not a prospective screening study.
- Cohort differences (age, storage) may confound results; external, prospective validation needed.
Future Directions: Prospective, population-based validation against low-dose CT, standardization of pre-analytics, and integration into surveillance algorithms with cost-effectiveness analyses.
Lung cancer remains the leading cause of cancer-related mortality worldwide, with recurrence or cancer-related death occurring even after curative-intent therapy. In this multicenter case-control study, we developed and validated a noninvasive urinary extracellular vesicle-derived microRNA (miRNA)-based assay for early-stage lung cancer detection and explored its utility for prognosis prediction and recurrence monitoring. Urine samples from 278 patients with lung cancer (half with early-stage disease) and 213 non-cancer controls were analyzed using small RNA sequencing and machine learning. The detection model showed high performance, with AUCs of 0.942 in the training and 0.941 in the test set. Sensitivity and specificity for early-stage lung cancer were 82.0% and 92.5% in the training set, and 88.2% and 87.0% in the test set, respectively. Twelve miRNAs decreased after surgery and rose again at recurrence. Eleven miRNAs were significantly associated with recurrence-free survival, and a 3-miRNA prognostic panel stratified patients into high- and low-risk groups with significantly different outcomes. Although systemic differences in age and sample storage between cohorts were observed, these findings suggest that urinary EV-miRNA profiling may be useful for early detection of lung cancer in a case-control setting and underscore its potential relevance for prognosis prediction and recurrence monitoring.
3. Early-life liquefied petroleum gas cooking intervention and lung function in Guatemalan children: A randomized clinical trial.
Among Guatemalan children in a randomized clean-cooking intervention, prespecified oscillometry outcomes at age 3 showed no differences between LPG and biomass arms. Exploratory analyses indicated lower resistance across frequencies with LPG, suggesting a potential benefit on airway caliber requiring further validation.
Impact: A randomized environmental intervention with objective lung function in early childhood informs the plausibility and limits of clean-cooking benefits.
Clinical Implications: Despite null primary outcomes at age 3, potential airway caliber benefits suggest continued emphasis on clean-cooking policies, while highlighting the need for longer follow-up and exposure–response targeting.
Key Findings
- Valid oscillometry obtained in 525 of 750 assessed 3-year-olds (70%).
- No significant differences in prespecified oscillometry outcomes (e.g., R7, X7, AX, R19, R7–R19).
- Exploratory analysis: lower resistance across frequencies in LPG arm (adjusted difference −0.31 cmH2O·s/L; 95% CI −0.59 to −0.03).
- Children with recent respiratory infection were excluded to reduce acute illness confounding.
Methodological Strengths
- Randomized intervention with objective oscillometry and artifact removal.
- Adjusted analyses for key child characteristics (height, weight, age, sex).
Limitations
- Country-specific analysis (Guatemala only) may limit generalizability of the multi-country trial.
- Primary outcomes were null and exploratory signals need confirmation; 30% lacked valid oscillometry at age 3.
Future Directions: Longitudinal lung function trajectories, exposure–response analyses, and replication across sites to determine durable benefits and optimal exposure reductions.
RATIONALE: Household air pollution is a risk factor for obstructive lung diseases. OBJECTIVES: We estimated the effect of an early-life liquefied petroleum gas cooking intervention on childhood lung function. METHODS: The multi-country Household Air Pollution Intervention Network trial randomized 800 pregnant women (9-19 weeks gestation, 18-34 years) in Guatemala to receive a gas cookstove and free fuel intervention or continue cooking with biomass until the child is aged 1 year. The present analysis includes only Guatemalan children. At age 3 years, we measured lung function using oscillometry at 7-41 Hertz (Tremoflo C-100, Thorasys). Outcomes were resistance and reactance at 7 Hertz, area of reactance, resistance at 19 Hertz, resistance difference between 7 and 19 Hertz, and, as exploration, resistance across frequencies. Upper airway artifacts were removed using Tremoflo software. The effect of the intervention was estimated using linear regression models, unadjusted and adjusted (height, weight, age, sex). Children with respiratory infections during a 7-day recall period were excluded. RESULTS: Valid oscillometry was obtained from 525/750 (70%) 3-year-olds. Among the 225 missed oscillometry tests, 129/750 (17%) were due to the children not being willing to perform the measurements. We did not find evidence of an effect on prespecified oscillometry outcomes. Exploratory analysis suggested that resistance across the frequency spectrum was lower in intervention than control participants (adjusted difference: -0.31 cmH2O*S/L, 95% CI: -0.59, -0.03). CONCLUSIONS: Gas cooking compared to biomass cooking from mid-gestation through infancy was not associated with improved prespecified oscillometry outcomes in 3-year-old children. However, lowered resistance across all frequencies in the intervention arm suggests the intervention may have positively impacted airway caliber. Further studies are warranted, including exposure-response analysis and lung function trajectories.